Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLARET: Alemtuzumab consolidation in CLL responders
2008-003012-35Phase 4Completed
- Sponsor
- Leeds Teaching Hospitals NHS Trust
- Start
- May 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Alemtuzumab consolidation with No consolidation (observation) (2 arms). Primary endpoint: Progression-free survival. Started May 2012; status: completed.
02
Drugs
alemtuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2008-003012-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003012-35.